Lorlatinib/Lorlatinib (Lorlatinib) is the first generation of targeted drugs

Lorlatinib/Lorlatinib is a third-generation targeted drug and an oral kinase inhibitor used to treat cancer. A kinase inhibitor is an enzyme inhibitor that can block the action of protein kinases. Lorlatinib is used to treat patients with metastatic non-small cell lung cancer with ALK positive mutations and has strong clinical activity in advanced ALK positive non-small cell lung cancer.

According to relevant trial data, the effect of lorlatinib on patients with brain metastases is as high as75%. Lorlatinib is already on the market in China, but the price is relatively expensive and is unaffordable for ordinary families. Patients can choose the overseas version of the drug. The drugs are officially marketed, but the manufacturers are different. Patients with high financial pressure can choose the overseas version. When purchasing overseas medicines, patients are most worried about the authenticity and effectiveness of the medicines. How do patients choose? First, choose the Ze version and choose medicines that are officially marketed overseas. The second choice is the formal way to purchase medicines. The reliable way is to go to overseas pharmaceutical factories to get medicines yourself, or to purchase medicines through regular domestic overseas pharmaceutical companies. Only in this way can the quality of medicines be ensured. Once the quality of medicines is guaranteed, the effects of imported medicines and generic medicines will be similar. On the contrary, buying substandard medicine not only wastes money, but more importantly, delays patient treatment. Regularly marketed generic drugs are priced more favorably, ranging from more than 3 to about 5 thousand per box. Patients can choose the drug version according to their own financial situation. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.